Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
about
Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215.HIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT Inhibitors3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changesA new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidineIn vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analoguesA mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavirIn vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidineCoresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.Structural determinants of HIV-1 reverse transcriptase stereoselectivity towards (beta)-L-deoxy- and dideoxy-pyrimidine nucleoside triphosphates: molecular basis for the combination of L-dideoxynucleoside analogs with non-nucleoside inhibitors in anThe in vitro ejection of zinc from human immunodeficiency virus (HIV) type 1 nucleocapsid protein by disulfide benzamides with cellular anti-HIV activityAntiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitorCombination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibilityActivities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitroThe human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein zinc ejection activity of disulfide benzamides and benzisothiazolones: correlation with anti-HIV and virucidal activitiesIncreased activation of the combination of 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine in the presence of hydroxyurea3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants.A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidineShould we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testingN348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistanceNonheritable cellular variability accelerates the evolutionary processes of cancerCDA: combinatorial drug discovery using transcriptional response modulesWhat does it take to synergistically combine sub-potent natural products into drug-level potent combinations?A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activitySystems Pharmacology and Rational Polypharmacy: Nitric Oxide-Cyclic GMP Signaling Pathway as an Illustrative Example and Derivation of the General CaseUsing drug exposure for predicting drug resistance - A data-driven genotypic interpretation toolThe HIV global pandemic: the development and emerging implication.Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of human immunodeficiency virus-infected patientsHIV-1 Transmission, Replication Fitness and Disease Progression.Clinically relevant genotype interpretation of resistance to didanosineA novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidineAnalysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1.Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutationsThe Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.Genotypic testing for human immunodeficiency virus type 1 drug resistance.DNA synthesis fidelity by the reverse transcriptase of the yeast retrotransposon Ty1.
P2860
Q27639579-71ED0852-95F0-4958-80CF-A3DC832977A2Q27670634-B1413DB3-24A8-4EF6-8DC4-55C276936038Q27764900-93E89FA4-529E-4830-82E8-D8BB5973BADAQ28343476-331C6EBB-4360-4641-831B-D103D5E6267DQ28343615-2BA19474-C524-4C0F-8E81-FC5CAB25F44AQ28344112-FAD3420D-E528-4AD6-82E2-4820A21FF206Q28344355-C240F9EA-CBCA-4EDE-9348-F65280467EB6Q28369167-406A43AD-126E-4DD5-8E5E-F69522C58D82Q28370034-2DFB5D6D-1D13-4038-8761-F839D63E5099Q28378778-E4C5DCEC-BBA5-4E47-B8E3-FF7B5E9BBCFBQ28378892-E9FD7FF7-638A-4A1B-9F06-25847F4A704BQ28378896-DAD913E4-07A0-4712-9360-358FA438FADBQ28378951-70DD46A9-5B18-4F18-8A29-2DDEE66B398AQ28379173-A06709EA-6A3C-4CC6-A923-2FB535FF30C4Q28379466-D3064C14-8550-4B75-B135-5D5118A21FE8Q28379471-714E754F-A9E5-4555-974F-CFB6E7F7ED2FQ28379497-87E27B4A-578E-4019-91B4-3A8B03B656CCQ28379499-CC5C5C1F-60C6-4721-AD4E-DE81EC438D3FQ28471687-42F428F6-E4F7-432D-9943-C1730836E827Q28471689-DA3E15DA-696C-4004-8F65-B2808F938EB4Q28482084-8078AFC7-5E79-4678-8EE1-B38262724B31Q28482122-F5E24261-AC1A-44DD-B95D-7B60D5A70C4FQ28485360-3D7DA61E-66CF-40C8-A711-8D66003E2B33Q28533996-0AECA04D-70C2-4FBD-9D05-F94B69BF730AQ28550867-652BF7F8-0662-49F9-9A53-B9AAEF975CA1Q30000270-E332ACA2-BCF2-42B6-9BB8-D819243E9AEAQ30429401-28ED9F37-E61C-4EB5-BAAA-1B9F67222984Q30666737-62C4F70F-65A0-457C-B51D-0A3C75CAEA2CQ31430709-646EABDD-3DA0-4F3D-9657-73A0D3E7D4B2Q33699597-306A19A5-6FBE-49D5-9BA6-E626F0925659Q33758570-FFDADC8D-7CAC-40B4-9F19-6F8E2AE2FC97Q33770146-5F6CA886-B250-4878-AF6A-66A48633A4C8Q33782477-E29B8C3E-4A3E-4112-88E2-6A86836E7C9EQ33785338-0A503258-AA97-48ED-96F3-EA30806BA79CQ33826453-7E6D171C-D2BD-4646-A9B3-7371C26058EFQ33869951-5C1367DC-8F82-4FF0-80E2-5CC37943DD0AQ33889635-ECBE98F3-BA3F-4E16-AC23-BD23439BF3A3Q33900459-C9053924-F773-4CEB-94DD-04EE5573CA80Q33906239-C7AA9A65-19F6-4038-9FE8-68A6705D7290Q33938993-629E746E-D529-476F-A946-E4FCD4C52FAD
P2860
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
description
1995 nî lūn-bûn
@nan
1995 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
@ast
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
@en
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
@nl
type
label
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
@ast
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
@en
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
@nl
prefLabel
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
@ast
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
@en
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
@nl
P2093
P356
P1433
P1476
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
@en
P2093
P304
P356
10.1126/SCIENCE.7542804
P407
P577
1995-08-01T00:00:00Z